RELEVANT study
Research type
Research Study
Full title
RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic cancer.
IRAS ID
239770
Contact name
Rille Pihlak
Contact email
Sponsor organisation
The University of Manchester
Duration of Study in the UK
0 years, 10 months, 28 days
Research summary
The prognosis for patients with pancreatic cancer is dismal. Due to short-lived treatment responses, pancreatic cancer is the 3rd and 5th most common cause of cancer death in the US and UK respectively, accounting for more than 5% of all deaths from cancer and is projected to become the second leading cause of cancer-related death by 2030.
Some of the aggressive chemotherapy regimens used in the treatment of patients with pancreas cancer result in improved survival but at the expense of increased toxicities. When making their initial decisions regarding therapeutic management of their disease, patients may choose to receive treatments that will potentially result in better survival outcomes prior to experiencing the side effects. It is not known if they would have made a different choice after experiencing the common side effects of the treatment, with the possible associated decreased quality of life.
In this study, it is planned to evaluate patients’ and physicians’ views on pancreatic cancer diagnosis, treatment received and patient’s goals, in an effort to understand what would be a meaningful outcome from treatment for these patients. Views in relation to treatment response, side effects and changes over time will also be assessed in addition to discrepancies between patient and physician responses.
Patients with newly diagnosed advanced pancreatic cancers defined as unresectable cancer seen at the Christie NHS Foundation Trust in the HPB new patients’ clinic will be recruited to the study.REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0293
Date of REC Opinion
1 May 2018
REC opinion
Favourable Opinion